AR121910A1 - UNA VACUNA CONTRA EL SARS-CoV-2 Y PREPARACIÓN DE LA MISMA - Google Patents

UNA VACUNA CONTRA EL SARS-CoV-2 Y PREPARACIÓN DE LA MISMA

Info

Publication number
AR121910A1
AR121910A1 ARP210101078A ARP210101078A AR121910A1 AR 121910 A1 AR121910 A1 AR 121910A1 AR P210101078 A ARP210101078 A AR P210101078A AR P210101078 A ARP210101078 A AR P210101078A AR 121910 A1 AR121910 A1 AR 121910A1
Authority
AR
Argentina
Prior art keywords
gene
preparation
cov
same
present
Prior art date
Application number
ARP210101078A
Other languages
English (en)
Inventor
Pankaj Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AR121910A1 publication Critical patent/AR121910A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona una construcción de ADN que comprende el gen S o la región del gen S1 de la proteína 2019-nCov spike-S. La construcción de ADN de la presente invención comprende un vector plasmídico de ADN que transporta el gen S o región del gen S1 de la proteína 2019-nCoV spike-S. El vector puede además comprender un gen que codifica el péptido señal IgE o un gen que codifica el péptido señal t-PA. La construcción de ADN de conformidad con la presente invención será además utilizada en la preparación de una composición inmunogénica o una vacuna para el tratamiento o la prevención del coronavirus o las enfermedades relacionadas.
ARP210101078A 2020-04-23 2021-04-22 UNA VACUNA CONTRA EL SARS-CoV-2 Y PREPARACIÓN DE LA MISMA AR121910A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202021017410 2020-04-23

Publications (1)

Publication Number Publication Date
AR121910A1 true AR121910A1 (es) 2022-07-20

Family

ID=78270337

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101078A AR121910A1 (es) 2020-04-23 2021-04-22 UNA VACUNA CONTRA EL SARS-CoV-2 Y PREPARACIÓN DE LA MISMA

Country Status (10)

Country Link
US (1) US20230174588A1 (es)
EP (1) EP4138908A1 (es)
JP (1) JP2023523423A (es)
KR (1) KR20230005265A (es)
CN (1) CN116075319A (es)
AR (1) AR121910A1 (es)
BR (1) BR112022021374A2 (es)
MX (1) MX2022013028A (es)
TW (1) TW202206598A (es)
WO (1) WO2021214703A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
CN115335390A (zh) * 2022-01-10 2022-11-11 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US20070270361A1 (en) * 2003-08-04 2007-11-22 Shan Lu Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
CN110951756B (zh) * 2020-02-23 2020-08-04 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用

Also Published As

Publication number Publication date
TW202206598A (zh) 2022-02-16
KR20230005265A (ko) 2023-01-09
US20230174588A1 (en) 2023-06-08
CN116075319A (zh) 2023-05-05
MX2022013028A (es) 2022-11-30
JP2023523423A (ja) 2023-06-05
BR112022021374A2 (pt) 2023-01-10
WO2021214703A1 (en) 2021-10-28
EP4138908A1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
AR121910A1 (es) UNA VACUNA CONTRA EL SARS-CoV-2 Y PREPARACIÓN DE LA MISMA
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
MX2023007574A (es) "vacuna de arn contra variantes de sars-cov-2.
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
CR20220618A (es) Nuevas proteinas de unión a repeticiones de anquirina y sus usos
CO2021007916A2 (es) Ácido ribonucleico (arn) que codifica para una proteína
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
PE20230430A1 (es) Composiciones y metodos para modular simultaneamente la expresion de genes
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
MX2022014161A (es) Vacunas contra sars-cov-2.
PE20230171A1 (es) Vacunas contra el coronavirus y metodos de uso
WO2023094713A3 (en) Coronavirus vaccine
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
CO6140071A2 (es) Poxvirus de mapache que expresa glicoproteinas de la rabia
CO2022017989A2 (es) Vacunas para la papilomatosis respiratoria recurrente y métodos para usar estas
MX2023000041A (es) Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
ATE473756T1 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
GT200200150A (es) Cadenas quimericas codificantes para proteinas inductoras de efectos contra virus